07

Dec2021

WHITEPAPER: Uncovering the Hidden Costs of Take-Home Cancer Drugs

In cancer care, patients often face increased anxiety and uncertainty about their future care pathway. This is paired with an immediate need for therapy to treat potentially aggressive disease. Coverage eligibility for THCD varies significantly across Canadian provinces, creating interprovincial differences. Gaps in coverage of THCDs across provinces lead to inequitable ... Read More

13

Sep2021

Welcome to the PDCI Team

PDCI Welcomes Véronique Scott & Ishan Kumar to the Team Ishan Kumar joins PDCI as Manager, Data Innovation and Insights. As a member of PDCI’s data insights team, Ishan’s role includes designing ... Read More

10

Aug2021

John Anacleto Joins PDCI as Director of Private Payer Strategies & Data Insights

John Anacleto Joins PDCI as Director of Private Payer Strategies & Data Insights Please join us in welcoming John to the PDCI Market Access Family! John joins ... Read More

03

Aug2021

PMPRB: Federal Court of Appeal quashes PMPRB Alexion / Soliris Decision

PMPRB: Federal Court of Appeal quashes PMPRB Alexion / Soliris Decision with Significant Implications for the New PMPRB Guidelines In a unanimous July 29 decision, the Federal Court of Appeal (FCA) overturned a Federal Court judicial review and quashed the PMPRB decision in ... Read More

26

Jul2021

Deadline Extended: PMPRB Notice and Comment

Deadline Extended: PMPRB Notice and Comment - New Price Tests for Grandfathered Medicines On July 15th, 2021, the PMPRB invited stakeholders to comment on three amendments to the regulations with responses due by August 15th 2021. PMPRB announced today that the deadline has been ... Read More

29

Jun2021

Welcome Jessica Birrell and Rachel Arcand to the PDCI Team!

PDCI Market Access has further expanded its Market Access Team! Jessica joins PDCI as Manager, Market Access.  She will be responsible for coordinating our pricing and market access projects including HTA and payer ... Read More

06

May2021

PMPRB Announces the Guideline Monitoring and Evaluation Plan (GMEP) Consultation

The PMPRB is developing a Guideline Monitoring and Evaluation Plan (GMEP) that will analyze trends in the pharmaceutical market before and after the implementation of the new framework to assess whether it is working as intended, and to inform the need for any future adjustments. The PMPRB ... Read More

14

Apr2021

NACI Process For Incorporating Economic Evidence Into Federal Vaccine Recommendations Consultation

BACKGROUNDThe National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.Traditionally, NACI reviewed safety, efficacy, immunogenicity, effectiveness and burden of illness in making recommendations for vaccine programs. PHAC has now expanded ... Read More

29

Mar2021

CADTH Releases Pharmaceuticals Reviews Update – Issue 22

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CADTH reimbursement review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.... Read More

15

Jan2021

PMPRB Proposes Amendments to New Guidelines: Requests Consultation from Stakeholders

On January 13th 2021, as a consequence of the new PMPRB coming-into-force date, PMPRB has invited stakeholders to comment on two proposed amendments to the New Guidelines.  The two amendments pertain to (A) the Definition of Gap Medicines and (B) Compliance Timelines with Maximum List ... Read More